Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

bioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests

Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecastsbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the
byBenzinga Newsdesk
June 12, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecasts

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath® Lung to patients since Jan. 1, 2024. CyPath® Lung is a noninvasive test to detect early-stage lung cancer.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

‘Asinine’ Cash Flow: Energy Analyst Revises Forecast On Energy Stocks, Crude Oil Prices – ‘Facts’ Have Changed

By AJ Fabino
July 27, 1:14 PM
Fundamentals will win, and shareholders will benefit from energy companies generating "asinine amounts" of free cash flow, says energy analysts at HFI Research. HFI is a contrarian investment research firm whose current focus is on the energy and natural gas markets.

CVX